More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$7.41B
EPS
-0.52
P/E ratio
--
Price to sales
17.03
Dividend yield
--
Beta
2.032617
Previous close
$54.99
Today's open
$55.47
Day's range
$52.67 - $56.73
52 week range
$15.18 - $102.81
show more
CEO
Serge Saxonov
Employees
1178
Headquarters
Pleasanton, CA
Exchange
Nasdaq Global Select
Shares outstanding
131534189
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations
Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform PLEASANTON, Calif., Nov. 16, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease.
PRNewsWire • Nov 16, 2026

10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
TXG's Xenium platform is set to power a 500-patient breast cancer biomarker study, expanding its oncology research footprint and precision diagnostics potential.
Zacks Investment Research • Nov 12, 2026

Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform
Study aims to identify biomarkers that could predict how patients with breast cancer respond to neoadjuvant therapy PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics Co. Ltd (SPDx), will deploy its Xenium platform in a 24-month study.
PRNewsWire • Nov 10, 2026

What 10x Genomics (TXG) Said on Its Q3 Earnings Call
10x Genomics NASDAQ: TXG raised its full-year revenue outlook after reporting modest third-quarter growth and increased its shipment target for its new Atera spatial biology platform.
MarketBeat • Nov 6, 2026

TXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook
10x Genomics raises its 2026 revenue outlook on strong Atera demand and spatial consumables growth, but production constraints and margin pressure remain challenges.
Zacks Investment Research • Nov 6, 2026

10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis
TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potential.
Zacks Investment Research • Nov 6, 2026

10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript
10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

10x Genomics Reports Third Quarter 2026 Financial Results
PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026.
PRNewsWire • Nov 5, 2026

10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.22 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell 10x Genomics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.